UT Southwestern Medical Center

Three approved drugs can curb COVID-19 virus replication

Established pharmaceuticals could offer faster solutions

Newswise — DALLAS – May 18, 2020 – Three drugs that are already approved by the Food and Drug Administration (FDA) or other international agencies can block the production of the novel coronavirus that causes COVID-19 in human cells, according to computational and pharmaceutical studies performed by UT Southwestern scientists.

These findings, published on a preprint server known as ChemRxiv on May 14 prior to peer review, build on other recent research by the same team to quickly find promising agents against this often serious respiratory condition.

COVID-19, caused by the SARS-CoV-2 virus, has now infected more than 4 million people and killed more than 300,000 worldwide since it emerged in December 2019. Scientists around the globe have focused their efforts on discovering potential vaccines and therapeutics to prevent and treat this disease. For example, recent studies have suggested that the anti-viral drug remdesivir shows some promise at reducing disease severity in COVID-19 patients. However, thus far, researchers have found no treatment or prophylaxis with clear evidence of clinical benefit across large populations.

Developing new pharmaceuticals could take months, even with rapid approval, according to study leaders Hesham Sadek, M.D., Ph.D., a professor of internal medicine, molecular biology, and biophysics; John W. Schoggins, Ph.D., an associate professor of microbiology; and Mahmoud Ahmed, Ph.D., an instructor of internal medicine. Thus, the UTSW researchers are testing drugs that are already approved by the FDA or other international agencies to see if they can attack this virus.

Recently, Sadek and his colleagues published a study in the same preprint server that used computer modeling to screen thousands of FDA-approved drugs for their ability to fit into the binding pocket of SARS-CoV-2’s main protease, an enzyme that the virus uses to chop up long strands of viral proteins.

“Each piece has individual functions that are really important to the virus to survive and replicate,” explains Schoggins, whose work focuses on viral infection and replication. “If the protease isn’t working because it’s blocked by another agent, the virus’s other functions fall apart.”

Many successful antiviral drugs, such as those that fight HIV and hepatitis C, are protease inhibitors, he adds.

In the new study, Sadek and his colleagues again used computer modeling to perform a more targeted screen of approved drugs, focusing on their ability to bind either in the central part of the protease binding pocket or the terminal part of the binding pocket, and/or to covalently bind in these regions – a type of chemical interaction that results in irreversible blockage of the protein.

“Even if the drug comes off the pocket,” Sadek says, “a covalent inhibitor forever changes the pocket’s characteristics, which makes it harder for the enzyme to do its job.”

Using this method, the team identified four promising candidates: atovaquone, a drug previously used to treat malaria that’s currently used to treat toxoplasmosis, babesiosis, and Pneumocystic pneumonia; mebendazole, a drug that’s used to treat several different parasitic worm infections; ouabain, a naturally occurring compound that was used as an arrow poison in Africa and is no longer approved in the U.S. but used in other parts of the world to treat heart failure; and dronedarone, a drug used to maintain heart rhythms.

Within a matter of weeks, Schoggins and his colleagues converted part of their laboratory space to a drug-screening facility equipped to safely handle SARS-CoV-2. The researchers first infected a line of nonhuman primate cells traditionally used to study viruses with SARS-CoV-2, then treated them with solutions with various concentrations of these drugs. Next, they performed tests to determine how much virus was in these cells to see how well SARS-CoV-2 was replicating.

Although dronedarone quickly showed toxic effects in these cells, the other three compounds effectively stemmed viral replication in doses similar or significantly lower than what’s currently used to clinically treat other diseases. These effects held true when the drugs were tested in infected human cells, although mebendazole’s effects weren’t as potent in the human cell line.

Of these three, atovaquone is uniquely promising, Sadek says. This drug is predicted to covalently attach to the protease binding pocket, does so at a dose lower than the therapeutic plasma concentrations currently used, has previously been reported to have anti-viral activity against other RNA viruses, and has a long and established history for treating another infectious disease that affects the lungs.

The team plans to continue studying this drug in animal models of COVID-19 to see if it can effectively fight this disease. In addition to these preclinical models, Sadek adds, he and his colleagues plan to test atovaquone in humans in clinical trials as soon as possible.

Other UTSW researchers who contributed to this study include Ayman B. Farag, Ping Wang, Ian N. Boys, Jennifer L. Eitson, Maikke B. Ohlson, Wenchun Fan, and Matthew B. McDougal.

Sadek holds the J. Fred Schoellkopf, Jr. Chair in Cardiology. Schoggins is a Nancy Cain and Jeffrey A. Marcus Scholar in Medical Research, in Honor of Dr. Bill S. Vowell.

About UT Southwestern Medical Center

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty has received six Nobel Prizes, and includes 22 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.


Filters close

Showing results

110 of 6084
Newswise: Public
Released: 28-Jul-2021 2:45 PM EDT
Highly Potent, Stable Nanobodies Stop SARS-CoV-2
Max Planck Society (Max-Planck-Gesellschaft)

Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its dangerous new variants.

Newswise: Public
Released: 28-Jul-2021 2:20 PM EDT
Psychological Consequences of COVID-19 in Health Care
University of Bonn

Physicians, nursing staff, medical technical assistants, and pastoral workers in hospitals: they have all been placed under severe strain by the Covid-19 pandemic.

Newswise: Public
Released: 28-Jul-2021 2:10 PM EDT
Why Lockdown in Africa Does Not Work as a First COVID-19 Pandemic Response
University of Johannesburg

In an African pandemic it is more productive to consider lockdowns, after using other non-medical measures first, Especially in countries with high levels of poverty and corruption, says Prof Nicholas Ngepah, a Professor of Economics at the University of Johannesburg in South Africa.

Newswise:Video Embedded how-to-talk-with-people-who-are-not-vaccinated-against-covid-19
Released: 28-Jul-2021 1:40 PM EDT
How to Talk With People Who Are Not Vaccinated Against COVID-19

Even though she has asthma, putting her at higher risk for severe complications from COVID-19, Angela Reeves-Flores, 33, waited until a week ago to get vaccinated.

Newswise: Indian Women’s Nutrition Suffered During COVID-19 Lockdown
Released: 28-Jul-2021 12:50 PM EDT
Indian Women’s Nutrition Suffered During COVID-19 Lockdown
Cornell University

A new study from Cornell University finds the nationwide lockdown India imposed last year in response to COVID-19 caused disruptions that negatively impacted women’s nutrition.

Released: 28-Jul-2021 12:00 PM EDT
MD Anderson Research Highlights for July 28, 2021
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a newly discovered protein that controls B cell survival, understanding epigenetic changes in malignant peripheral nerve sheath tumors (MPNSTs) and melanoma, identifying a protein that protect genome stability, developing novel cell therapies for COVID-19, a new option for treating neuropathic pain, exosome delivery of CRISPR/Cas9 to pancreatic cancer, discovering how cancer cells tolerate aneuploidy and the role of health disparities in long-term survival of adolescent and young adult patients with Hodgkin lymphoma.

Released: 28-Jul-2021 11:30 AM EDT
Study Reveals Characteristics of SARS-CoV-2 Spike Protein
University of Kentucky

A new University of Kentucky College of Medicine study published in the Journal of Biological Chemistry provides foundational information about SARS-CoV-2’s spike protein.

access_time Embargo lifts in 2 days
Embargo will expire: 4-Aug-2021 9:00 AM EDT Released to reporters: 28-Jul-2021 11:15 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 4-Aug-2021 9:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: UIC Awarded $6 Million to Develop Potential COVID-19 Treatment
Released: 28-Jul-2021 10:15 AM EDT
UIC Awarded $6 Million to Develop Potential COVID-19 Treatment
University of Illinois Chicago

Researchers at the University of Illinois Chicago are developing a potential treatment for COVID-19, thanks to a $6 million technology and therapeutic development award from the U.S. Department of Defense supporting pre-clinical animal studies.

Newswise: Don’t Let the Raging Virus Put Life in Jeopardy. Chula Recommends How to Build an Immunity for Your Heart Against Stress and Depression
Released: 28-Jul-2021 8:55 AM EDT
Don’t Let the Raging Virus Put Life in Jeopardy. Chula Recommends How to Build an Immunity for Your Heart Against Stress and Depression
Chulalongkorn University

Cumulative stress, denial, and chronic depression are the byproducts of the COVID-19 pandemic. The Center for Psychological Wellness, Chulalongkorn University recommends ways to cope by harnessing positive energy from our heart.

Showing results

110 of 6084